Stock 2137 BRII BIOSCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Brii Biosciences Limited

Equities

2137

KYG1645A1094

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
1.09 HKD +9.00% Intraday chart for Brii Biosciences Limited +18.48% -52.19%
Mar. 25 Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
Mar. 22 Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With regards to fundamentals, the enterprise value to sales ratio is at 1.21 for the current period. Therefore, the company is undervalued.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BRII BIOSCIENCES LIMITED Stock Brii Biosciences Limited
-52.19% 93.15M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.62% 104B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.16% 97.42B
B+
ARGENX SE Stock argenx SE
+0.90% 22.2B
B
BIONTECH SE Stock BioNTech SE
-18.04% 21.23B
B+
GENMAB A/S Stock Genmab A/S
-10.65% 18.33B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.78% 15.06B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.40% 13.98B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.72% 11.66B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2137 Stock
  4. Ratings Brii Biosciences Limited